SEP 28·SEC EDGARLow
Jarrett Jennifer purchased $253K of DMRA
Jarrett Jennifer (Director, President and CEO) purchased 12,500 shares of Damora Therapeutics, Inc. (DMRA) at $20.23 ($0.25M total) on 2026-09-25.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$DMRA
Damora Therapeutics, Inc.
Price · $DMRAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $DMRA in the last 7 days.
Insider · 30dAll trades →
- Buys
- $253K 1 txs
- Sells
- — 0 txs
Jarrett Jennifer1× · $253K
10b5-1 share of filings0%
Top stories · $DMRAMore →
SEP 3·rttnews.com
Damora Therapeutics Grants Inducement Awards To Three New Employees
Damora Therapeutics (DMRA), a biotech firm, granted equity awards to three new employees. The awards include options for 135,400 shares, vesting over four years, with an exercise price of $28.18 per share. DMRA's stock closed at $28.18, up 0.14%.
JUL 20·SEC EDGAR 8-K
Damora Therapeutics, Inc. (DMRA): Entry into a Material Definitive Agreement
Damora Therapeutics, Inc. (DMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 3 dmra-ex3_1.htm EX-3.1 EX-3.1 Exhibit 3.1 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES Memorandum OF association of Damora Therapeutics, Inc. (ADOPTED BY SPECIAL RESOLUTION PASSED ON 9 FEBRUARY 2026 AND EFFECTIVE AS OF 16 JULY 2026) THE COMPANIES ACT (AS AMEND
DMRA sentiment & insider activity
Recent DMRA coverage spans corporate actions and insider activity.
In the last 30 days, DMRA insiders filed 1 SEC Form 4 transaction — 1 purchase ($253K) and no sales. The most active reporter was Jarrett Jennifer, Director, President and CEO, with 1 filing.
What's driving DMRA
Insider purchase may signal confidence, modest bullish pressure.
Small dilution from option grants; limited immediate price impact.
The filing confirms a material definitive agreement exists, but the excerpt does not disclose deal terms, counterparties, or financial impact.
Corporate domicile change with a new CUSIP, but no stated change to business, management, assets, or liabilities.
Routine shareholder-meeting outcomes; limited direct fundamental signal beyond governance/board continuity.
AlphAI scores every news story that mentions DMRA with an AI model for sentiment and relevance, and aggregates insider trades from Damora Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $DMRA
Score
Jarrett Jennifer purchased $253K of DMRA
Jarrett Jennifer (Director, President and CEO) purchased 12,500 shares of Damora Therapeutics, Inc. (DMRA) at $20.23 ($0.25M total) on 2026-09-25.
1 min readDamora Therapeutics Grants Inducement Awards To Three New Employees
Damora Therapeutics (DMRA), a biotech firm, granted equity awards to three new employees. The awards include options for 135,400 shares, vesting over four years, with an exercise price of $28.18 per share. DMRA's stock closed at $28.18, up 0.14%.
1 min readDamora Therapeutics, Inc. (DMRA): Entry into a Material Definitive Agreement
Damora Therapeutics, Inc. (DMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 3 dmra-ex3_1.htm EX-3.1 EX-3.1 Exhibit 3.1 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES Memorandum OF association of Damora Therapeutics, Inc. (ADOPTED BY SPECIAL RESOLUTION PASSED ON 9 FEBRUARY 2026 AND EFFECTIVE AS OF 16 JULY 2026) THE COMPANIES ACT (AS AMEND
2 min readDamora Therapeutics, Inc.: Damora Announces Redomestication from Delaware to Cayman Islands
Damora Therapeutics (NASDAQ: DMRA) said it completed its redomestication from Delaware to the Cayman Islands effective July 16, 2026. Each Delaware common share converted into one ordinary share, and preferred shares into corresponding preferred shares. From July 20, 2026, ordinary shares trade on Nasdaq under a new CUSIP while the ticker remains DMRA; the company said business and obligations are unchanged.
2 min readDamora Therapeutics, Inc. (DMRA): Submission of Matters to a Vote of Security Holders
Damora Therapeutics, Inc. (DMRA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001800315 0001800315 2026-04-28 2026-04-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17 ,
2 min read